Mir-17-92 Promotes Leukemogenesis in Chronic Myeloid Leukemia Via Targeting A20 and Activation of NF-κB Signaling

Qinghua Jia,Huiyan Sun,Fengjun Xiao,Yan Sai,Qingfang Li,Xiaoyan Zhang,Shuang Yang,Hengxiang Wang,Hua Wang,Yuefeng Yang,Chu-Tse Wu,Lisheng Wang

DOI: https://doi.org/10.1016/j.bbrc.2017.04.144

IF: 3.1

2017-01-01

Biochemical and Biophysical Research Communications

Abstract:miR-17-92 cluster are overexpressed in hematological malignancies including chronic myeloid leukemia (CML). However, their roles and mechanisms that regulate BCR-ABL induced leukemogenesis remain unclear. In this study, we demonstrated that genomic depletion of miR-17-92 inhibited the BCR-ABL induced leukemogenesis by using a mouse model of transplantation of BCR-ABL transduced hematopoietic stem cells. Furthermore, we identified that miR-19b targeted A20 (TNFAIP3). A20 overexpression results in inactivation of NF-κB activity including decrease of phosphorylation of P65 and IκBα, leads to induce apoptosis and inhibit proliferation and cycle in CML CD34 + cells. Thus we proved that miR-17-92 is a critical contributor to CML leukemogenesis via targeting A20 and activation of NF-κB signaling. These findings indicate that miR-17-92 will be important resources for developing novel treatment strategies of CML and better understanding long-term disease control.